Welcome to our dedicated page for Fibrogen SEC filings (Ticker: FGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings archive for FibroGen, Inc. (FGEN) provides regulatory documents that trace the company’s evolution into Kyntra Bio, Inc. A Form 8-K filed in January 2026 reports a Certificate of Amendment to the Amended and Restated Certificate of Incorporation, changing the company’s name from FibroGen, Inc. to Kyntra Bio, Inc. The same filing notes that the company’s common stock, formerly trading under the symbol FGEN, began trading on Nasdaq under the symbol KYNB on January 8, 2026, with the CUSIP number unchanged.
Other Form 8-K filings in this archive document key corporate events and financial updates. These include reports on quarterly financial results, amendments to financing agreements, and the completion of the sale of FibroGen International (Hong Kong) Ltd. (FibroGen China) to AstraZeneca Treasury Limited. The filings describe the total consideration for that transaction, the inclusion of all roxadustat assets in China, and the subsequent repayment of a senior secured term loan.
Investors can use these filings to understand how the company presents its business, capital structure, and strategic transactions to regulators. While detailed annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transaction reports (such as Form 4) are not listed in the provided data, the available 8-Ks illustrate how FibroGen, now Kyntra Bio, communicates material events, including regulatory approvals related to the China divestiture and financial condition updates.
On Stock Titan, these historical FGEN filings are paired with AI-powered tools that help interpret complex disclosures, highlight significant items in event-driven reports, and connect corporate actions—such as the name change, asset sale, and financing amendments—to the broader narrative of the company’s transformation into Kyntra Bio.
Kyntra Bio, Inc., formerly FibroGen, is a biopharmaceutical company focused on cancer and anemia, highlighted by a 2025 rebranding and new Nasdaq symbol KYNB. The company’s lead oncology asset is FG-3246, a CD46-targeting antibody-drug conjugate for metastatic castration-resistant prostate cancer, now in a Phase 2 monotherapy dose-optimization trial with an FG-3180 PET imaging companion.
Kyntra continues to develop roxadustat, already approved for chronic kidney disease anemia in multiple territories through partners, while preparing a Phase 3 trial in lower-risk myelodysplastic syndromes after FDA alignment and Orphan Drug Designation in 2025. In August 2025, it sold its China roxadustat operations to AstraZeneca for $220.4 million, retaining rights in the U.S., Canada, Mexico and other markets. Revenue is primarily driven by collaborations with Astellas and AstraZeneca, supported by a revenue-interest financing with NovaQuest and an exclusive option to acquire Fortis Therapeutics, which licensed FG-3246.
Kyntra Bio reported fourth quarter and full-year 2025 results and highlighted progress in its oncology and rare disease pipeline. The company is running a Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer, with an interim analysis planned in the second half of 2026, and reported encouraging investigator-sponsored combination data with enzalutamide presented at ASCO meetings.
Kyntra submitted a pivotal Phase 3 protocol for roxadustat in anemia due to lower-risk myelodysplastic syndromes to the FDA and is evaluating whether to advance this program alone or with a partner. Total revenue from continuing operations fell to $6.4 million in 2025 from $29.6 million in 2024, but the net loss from continuing operations narrowed to $58.2 million from $153.1 million, reflecting a restructuring and portfolio shift. The company ended 2025 with $109.4 million in cash, cash equivalents, investments, and accounts receivable and currently expects this to fund operating plans into 2028.
KYNTRA BIO, INC. CEO and director Thane Wettig reported a routine tax-related share disposition. On March 6, 2026, 277 shares of common stock were withheld by the issuer at $6.84 per share to satisfy taxes due upon the vesting of restricted stock units. After this withholding, Wettig held 24,403 common shares directly, and an additional 40 shares were held indirectly by his spouse.
KYNTRA BIO, INC. Chief Financial Officer David DeLucia reported a small tax-related share disposition. On the vesting of restricted stock units, 60 shares of common stock were withheld by the company to cover his tax obligations. After this withholding, he directly owns 4,429 common shares.
This was a tax-withholding disposition, not an open-market sale or purchase, so it mainly reflects routine equity compensation mechanics rather than a change in his investment view on the company.
FibroGen Inc. Schedule 13G/A: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 400,000 shares of common stock, representing 9.89% of the class as of 12/31/2025. The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder, and that the Master Fund has the right to receive dividends or sale proceeds. Steven Boyd is identified as managing member of Armistice Capital and files jointly with the firm.
Kyntra Bio, Inc. reported that CEO and director Thane Wettig received a grant of stock options. On February 3, 2026, he was awarded options to purchase 60,000 shares of common stock at an exercise price of $8.50 per share, with no cash price paid for the grant itself.
The options vest in equal amounts quarterly over four years starting from February 3, 2026, and are exercisable until February 2, 2036. Following this award, Wettig beneficially owns 60,000 stock options, held directly.
Kyntra Bio, Inc. reported an option grant to its Chief Financial Officer, David DeLucia. On 02/03/2026, he was awarded a stock option for 26,000 shares of common stock at an exercise price of $8.50 per share.
The option vests in equal amounts quarterly over four years starting on 02/03/2026. Following this grant, DeLucia beneficially owns 26,000 derivative securities directly through this option award.
FibroGen, Inc. has changed its corporate name to Kyntra Bio, Inc. following the filing of a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the State of Delaware on December 29, 2025. The name change becomes effective at 4:30 p.m. Eastern Time on January 7, 2026.
The board also approved a conforming amendment to the company’s Bylaws, effective at the same time, to update the Bylaws’ title to Kyntra Bio, Inc. In connection with the rebranding, the company’s common stock, previously trading under the symbol “FGEN” on The Nasdaq Global Select Market, will begin trading under the new symbol “KYNB” at the market open on January 8, 2026. The CUSIP number for the common stock remains unchanged.
FibroGen, Inc. (FGEN) reported insider buying by its Chief Executive Officer and Director in a Form 4 filing. On 11/13/2025, the reporting person purchased 1,000 shares of common stock at $9.18 per share. On 11/17/2025, an additional 2,700 shares were purchased at $9.0999 per share. After these transactions, the reporting person beneficially owned 24,939 shares of FibroGen common stock directly and 40 shares indirectly through a spouse. The filing was made by a single reporting person in the roles of both CEO and Director.
FibroGen, Inc. (FGEN) reported Q3 2025 results highlighted by the divestiture of its China operations to AstraZeneca for total consideration of $220.4 million. The company received $210.4 million at closing on August 29, 2025 and used approximately $80.9 million to repay its senior secured term loan facilities, interest, and related fees.
Results reflect discontinued operations for China: income from discontinued operations was $213.8 million in the quarter, including a $52.2 million gain on divestiture. From continuing operations, revenue was $1.1 million and loss was $13.1 million. Net income was $200.6 million, driven by the discontinued operations gain. Cash and cash equivalents were $118.0 million as of September 30, 2025, up from $50.5 million at year-end 2024.
The company effected a 1‑for‑25 reverse stock split on June 16, 2025. Shares outstanding were 4,045,445 as of October 31, 2025. Management now believes existing cash will fund planned operating requirements for at least 12 months following issuance. FibroGen initiated a Phase 2 study of FG‑3246 in mCRPC and aligned with the FDA on key elements of a planned Phase 3 for roxadustat in lower‑risk MDS.